Topical HPMC/S-Nitrosoglutathione Solution Decreases Inflammation and Bone Resorption in Experimental Periodontal Disease in Rats

PLoS One. 2016 Apr 26;11(4):e0153716. doi: 10.1371/journal.pone.0153716. eCollection 2016.

Abstract

S-nitrosoglutathione (GSNO) is a nitric oxide (NO) donor, which exerts antioxidant, anti-inflammatory, and microbicidal actions. Intragingival application of GSNO was already shown to decrease alveolar bone loss, inflammation and oxidative stress in an experimental periodontal disease (EPD) model. In the present study, we evaluated the potential therapeutic effect of topical applications of hydroxypropylmethylcellulose (HPMC)/GSNO solutions on EPD in Wistar rats. EPD was induced by placing a sterilized nylon (3.0) thread ligature around the cervix of the second left upper molar of the animals, which received topical applications of a HPMC solutions containing GSNO 2 or 10 mM or vehicle (HPMC solution), 1 h prior to the placement of the ligature and then twice daily until sacrifice on day 11. Treatment with HPMC/GSNO 10 mM solution significantly reduced alveolar bone loss, oxidative stress and TNF-α e IL-1β levels in the surrounding gingival tissue, and led to a decreased transcription of RANK and TNF-α genes and elevated bone alkaline phosphatase, compared to the HPMC group. In conclusion, topical application of HPMC/GSNO solution is a potential treatment to reduce inflammation and bone loss in periodontal disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Alveolar Bone Loss / drug therapy
  • Alveolar Bone Loss / metabolism
  • Alveolar Bone Loss / pathology
  • Animals
  • Disease Models, Animal
  • Gingiva / drug effects
  • Gingiva / metabolism
  • Hypromellose Derivatives / administration & dosage*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Inflammation / pathology
  • Interleukin-1beta / metabolism
  • Male
  • Nitric Oxide Donors / administration & dosage
  • Nitric Oxide Synthase Type II / metabolism
  • Periodontal Diseases / drug therapy*
  • Periodontal Diseases / metabolism
  • Periodontal Diseases / pathology
  • Rats
  • Rats, Wistar
  • Receptor Activator of Nuclear Factor-kappa B / metabolism
  • S-Nitrosoglutathione / administration & dosage*
  • Solutions
  • Tartrate-Resistant Acid Phosphatase / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Interleukin-1beta
  • Nitric Oxide Donors
  • Receptor Activator of Nuclear Factor-kappa B
  • Solutions
  • Tumor Necrosis Factor-alpha
  • Hypromellose Derivatives
  • S-Nitrosoglutathione
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Tartrate-Resistant Acid Phosphatase

Grants and funding

Leitao RFC and de Oliveira MG would like to acknowledge grants from The National Council for Scientific and Technological Development - CNPq (http://www.cnpq.br/) (projects #478380/2011-9 and 309390/2011-7, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.